BioCentury | May 17, 2004
Company News

Corautus board of directors update

...a managing partner at Merriman Partners; and F. Richard Nichol, retired chairman and CEO of CoCensys...
BioCentury | Jan 10, 2000
Company News

Dura board of directors update

...Diego, Calif. Business: Autoimmune/Inflammation, Pulmonary Appointed: F. Richard Nichol, retired president, CEO and chairman of CoCensys Inc....
BioCentury | Jan 4, 2000
Finance

1999 M&A activity

...Medinor $7.3 Procept Pacific Pharma $6.4 Avecia Boston Biosystems $6.0 Parexel CEMAF $6.0 Purdue Pharma CoCensys...
BioCentury | Sep 27, 1999
Company News

CoCensys, Purdue Pharma deal

...all outstanding shares of COCN for $1.16 per share in cash (see BioCentury, Aug. 9). CoCensys Inc....
BioCentury | Aug 16, 1999
Company News

Amylin Pharmaceuticals Inc management update

...of regulatory affairs and quality assurance, formerly EVP of product development and regulatory affairs at CoCensys Inc. WIR...
BioCentury | Aug 9, 1999
Finance

Cephalon puts resurrection to vote

...up $0.625 on the week, while CYP finished at $2, down $0.125 (see Noteworthy, A4). CoCensys...
BioCentury | Aug 9, 1999
Company News

CoCensys, Purdue Pharma deal

...assumption of debt and purchase of preferred stock outstanding, is expected to be $9.5 million. CoCensys Inc....
BioCentury | May 24, 1999
Company News

CoCensys, Cytovia, Domain Associates LLC deal

...Cytovia, which develops apoptosis inhibitors and screening cell technology, to Domain (see BioCentury, May 17). CoCensys Inc....
BioCentury | May 17, 1999
Company News

CoCensys, Cytovia, Domain Associates LLC deal

...of its Cytovia shares. After the repurchase, $1.9 million in preferred stock will remain outstanding. CoCensys Inc....
BioCentury | May 3, 1999
Company News

CoCensys neurological news

...of $805,000 in the first quarter, and had $9 million in cash at March 31. CoCensys Inc....
Items per page:
1 - 10 of 94
BioCentury | May 17, 2004
Company News

Corautus board of directors update

...a managing partner at Merriman Partners; and F. Richard Nichol, retired chairman and CEO of CoCensys...
BioCentury | Jan 10, 2000
Company News

Dura board of directors update

...Diego, Calif. Business: Autoimmune/Inflammation, Pulmonary Appointed: F. Richard Nichol, retired president, CEO and chairman of CoCensys Inc....
BioCentury | Jan 4, 2000
Finance

1999 M&A activity

...Medinor $7.3 Procept Pacific Pharma $6.4 Avecia Boston Biosystems $6.0 Parexel CEMAF $6.0 Purdue Pharma CoCensys...
BioCentury | Sep 27, 1999
Company News

CoCensys, Purdue Pharma deal

...all outstanding shares of COCN for $1.16 per share in cash (see BioCentury, Aug. 9). CoCensys Inc....
BioCentury | Aug 16, 1999
Company News

Amylin Pharmaceuticals Inc management update

...of regulatory affairs and quality assurance, formerly EVP of product development and regulatory affairs at CoCensys Inc. WIR...
BioCentury | Aug 9, 1999
Finance

Cephalon puts resurrection to vote

...up $0.625 on the week, while CYP finished at $2, down $0.125 (see Noteworthy, A4). CoCensys...
BioCentury | Aug 9, 1999
Company News

CoCensys, Purdue Pharma deal

...assumption of debt and purchase of preferred stock outstanding, is expected to be $9.5 million. CoCensys Inc....
BioCentury | May 24, 1999
Company News

CoCensys, Cytovia, Domain Associates LLC deal

...Cytovia, which develops apoptosis inhibitors and screening cell technology, to Domain (see BioCentury, May 17). CoCensys Inc....
BioCentury | May 17, 1999
Company News

CoCensys, Cytovia, Domain Associates LLC deal

...of its Cytovia shares. After the repurchase, $1.9 million in preferred stock will remain outstanding. CoCensys Inc....
BioCentury | May 3, 1999
Company News

CoCensys neurological news

...of $805,000 in the first quarter, and had $9 million in cash at March 31. CoCensys Inc....
Items per page:
1 - 10 of 94